Loading company
$0.65+0.5%Nov 13 close
Next earnings: November 16, 2026 · after the close
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Past performance
- 1W
- +1.4%
- 1M
- -11.1%
- 3M
- -30.3%
- 6M
- -77.3%
- 1Y
- -65.2%
- 5Y
- -96.7%
$0.65+0.5%Nov 13 close
Next earnings: November 16, 2026 · after the close
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Dare Bioscience, Inc. is scheduled to report next on November 16, 2026, after the close. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $187.5K | -$21.2K | +985.82% |
| Profit | -$3M | -$4M | +25.74% |
| Profit per share | -$0.20 | -$0.45 | +55.56% |
| Free Cash Flow | -$6.9M | -$5.3M | -30.23% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The launch of Flora Sync LF5, our first directly commercialized product, represents an important milestone in the strategy Daré has pursued since its founding, to bring to market evidence-based products specifically designed for women,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Dare Bioscience, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Dare Bioscience, Inc. has no earnings call transcript available.